Open | - |
Close | - |
Volume / Avg. | 1.221K / 319.633K |
Day Range | - - - |
52 Wk Range | 1.620 - 24.710 |
Market Cap | $110.803M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 37 |
Short Interest | % |
Days to Cover | 4.7 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Vistagen Therapeutics (NASDAQ: VTGN) through any online brokerage.
Other companies in Vistagen Therapeutics’s space includes: Vincerx Pharma (NASDAQ:VINC), Outlook Therapeutics (NASDAQ:OTLK), Anixa Biosciences (NASDAQ:ANIX), Barinthus Biotherapeutics (NASDAQ:BRNS) and Adagene (NASDAQ:ADAG).
The latest price target for Vistagen Therapeutics (NASDAQ: VTGN) was reported by Jefferies on Thursday, December 7, 2023. The analyst firm set a price target for 15.00 expecting VTGN to rise to within 12 months (a possible 265.85% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Vistagen Therapeutics (NASDAQ: VTGN) is $4.1 last updated Today at March 19, 2024 at 7:43 AM EDT.
There are no upcoming dividends for Vistagen Therapeutics.
Vistagen Therapeutics’s Q3 earnings are confirmed for Tuesday, February 13, 2024.
There is no upcoming split for Vistagen Therapeutics.
Vistagen Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.